Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
OKYO OKYO Pharma
- 1.060
- -0.030-2.75%
Close Dec 20 16:00 ET
- 1.090
- +0.030+2.83%
Post 20:01 ET
35.87MMarket Cap-1.86P/E (TTM)
1.090High1.040Low30.54KVolume1.060Open1.090Pre Close32.60KTurnover0.13%Turnover RatioLossP/E (Static)33.84MShares1.95052wk High-6.09P/B25.36MFloat Cap0.80852wk Low--Dividend TTM23.92MShs Float7.000Historical High--Div YieldTTM4.59%Amplitude0.808Historical Low1.067Avg Price1Lot Size
OKYO Pharma Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2024 | (FY)Mar 31, 2023 | (FY)Mar 31, 2022 | (FY)Mar 31, 2021 | (FY)Mar 31, 2020 | (FY)Mar 31, 2019 | (FY)Mar 31, 2018 | (FY)Mar 31, 2017 | (FY)Mar 31, 2016 | (FY)Mar 31, 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -23.33%-9.49M | -40.73%-7.7M | -241.71%-5.47M | -33.12%-1.6M | 39.59%-1.2M | -24.77%-1.99M | -144.89%-1.59M | -0.06%-651.27K | 91.85%-650.88K | -131.16%-7.98M |
| Net income from continuing operations | -26.49%-16.8M | -113.65%-13.28M | -84.03%-6.22M | -108.50%-3.38M | 66.95%-1.62M | 82.66%-4.9M | -11,584.05%-28.27M | 70.50%-241.93K | 90.06%-820.17K | 40.72%-8.26M |
| Operating gains losses | 7.80%55.18K | 644.07%51.19K | -390.58%-9.41K | -76.73%3.24K | 1,292.03%13.92K | -100.00%-1.17K | --26.39M | ---- | -127.31%-26.9K | 77.71%98.48K |
| Depreciation and amortization | 1.82%3.87K | 62.89%3.8K | -82.22%2.33K | 119.28%13.11K | 2,644.97%5.98K | --217.8166 | --0 | ---- | ---- | ---- |
| Other non cash items | 2,912.53%3.46M | 86.31%114.99K | -25.64%61.72K | 93.73%83.01K | -98.40%42.85K | 991.02%2.69M | --246.21K | ---- | 28.53%-12.36K | -517.57%-17.29K |
| Change In working capital | -32.35%2.67M | 485.38%3.95M | -197.99%-1.02M | 460.14%1.04M | 5.50%186.53K | 395.04%176.81K | 108.35%35.72K | -491.19%-427.71K | 246.35%109.34K | -34.37%-74.71K |
| -Change in receivables | --0 | --0 | -86.65%27.38K | 267.09%205.07K | 6.41%-122.73K | -165.98%-131.14K | 155.03%198.76K | -584.16%-361.21K | 1,536.60%74.61K | 94.94%-5.19K |
| -Change in payables and accrued expense | -41.00%2.23M | 1,616.75%3.78M | -129.66%-249.09K | 171.54%839.78K | 0.43%309.27K | 288.88%307.95K | -145.16%-163.04K | -291.48%-66.51K | 149.96%34.73K | -247.53%-69.52K |
| -Change in other current assets | 162.50%440.26K | 120.91%167.72K | ---802.15K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | 0 | 6.56M | ||||||||
| Operating cash flow | -23.33%-9.49M | -40.73%-7.7M | -241.71%-5.47M | -33.12%-1.6M | 39.59%-1.2M | -24.77%-1.99M | -144.89%-1.59M | -0.06%-651.27K | 54.08%-650.88K | 58.95%-1.42M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | -254.46%-5.92K | 90.79%-1.67K | 86.35%-18.11K | -9,931.22%-132.67K | -1.32K | 0 | 87.85%-335.18K | 73.95%-2.76M | |
| Capital expenditure reported | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 85.28%-405.59K | 73.48%-2.75M |
| Net PPE purchase and sale | --0 | -254.46%-5.92K | 75.96%-1.67K | ---6.94K | --0 | ---1.32K | --0 | ---- | 1,552.67%70.41K | 97.67%-4.85K |
| Net other investing changes | ---- | ---- | ---- | 91.58%-11.17K | ---132.67K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | -254.46%-5.92K | 90.79%-1.67K | 86.35%-18.11K | -9,931.22%-132.67K | ---1.32K | --0 | ---- | 87.85%-335.18K | 73.95%-2.76M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -33.41%6.21M | 332.99%9.32M | -72.49%2.15M | 712.50%7.83M | 963.31K | 0 | -96.66%12.36K | -96.45%370.51K | ||
| Net issuance payments of debt | --0 | --2M | --0 | 27,839.94%7.58M | ---27.33K | --0 | ---- | ---- | -28.53%12.36K | --17.29K |
| Net common stock issuance | -15.22%6.21M | --7.32M | --0 | -76.78%230.02K | --990.64K | --0 | ---- | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | --0 | --0 | 13,468.18%2.15M | --15.87K | --0 | ---- | ---- | ---- | ---- | 56.50%353.22K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -33.41%6.21M | 332.99%9.32M | -72.49%2.15M | 712.50%7.83M | --963.31K | --0 | ---- | ---- | -96.66%12.36K | -96.45%370.51K |
| Net cash flow | ||||||||||
| Beginning cash position | 49.79%4.05M | -60.80%2.7M | 2,825.59%6.89M | -62.48%235.49K | -76.03%627.62K | -40.60%2.62M | 0.23%4.41M | -29.89%4.4M | -40.36%6.27M | -33.03%10.52M |
| Current changes in cash | -302.32%-3.28M | 148.91%1.62M | -153.42%-3.32M | 1,771.58%6.21M | 81.35%-371.42K | -24.85%-1.99M | -144.89%-1.59M | 33.11%-651.27K | 74.42%-973.71K | -5.32%-3.81M |
| Effect of exchange rate changes | 122.88%63.5K | 68.18%-277.54K | -295.89%-872.14K | 2,249.98%445.22K | ---20.71K | ---- | ---- | --0 | 30.64%-171.84K | 8.21%-247.75K |
| End cash Position | -79.56%826.85K | 49.79%4.05M | -60.80%2.7M | 2,825.59%6.89M | -62.48%235.49K | -77.70%627.56K | -24.91%2.81M | -26.93%3.75M | -20.67%5.13M | -45.32%6.47M |
| Free cash flow | -23.24%-9.49M | -40.80%-7.7M | -240.34%-5.47M | -33.70%-1.61M | 39.63%-1.2M | -24.85%-1.99M | -144.89%-1.59M | 38.38%-651.27K | 74.70%-1.06M | 70.38%-4.18M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- |